-
Mashup Score: 46Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs - 1 month(s) ago
AbstractAims. In clinical practice, many patients do not reach the recommended treatment targets for LDL-cholesterol levels. We aimed to examine treatment patte
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 47Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs - 3 month(s) ago
AbstractAims. In clinical practice, many patients do not reach the recommended treatment targets for LDL-cholesterol levels. We aimed to examine treatment patte
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 32
AbstractAims. Using rosuvastatin, the RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe com
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 32
AbstractAims. Using rosuvastatin, the RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe com
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 32
AbstractAims. Using rosuvastatin, the RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe com
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES - 6 month(s) ago
Background: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C l
Source: www.ahajournals.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8Inclisiran and cardiovascular events: a comprehensive... : Current Opinion in Cardiology - 6 month(s) ago
an significantly lowers LDL-C levels, as shown by phase III studies, by inhibiting hepatic synthesis of proprotein convertase subtilisin kexin 9 (PCSK-9), a protein implicated in the degradation of LDL receptors. Inclisiran has the benefit of subcutaneous injection twice a year, which may reduce patient nonadherence when compared with other LDL-C reducing therapies such as statins and ezetimibe, which require daily dosing. When added on top of statins, a greater proportion of patients achieved recommended cholesterol goals. It has also demonstrated a good safety profile with few adverse effects. Summary Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Although it has been demonstrated to be effective in decreasing LDL-C, further research is n
Source: journals.lww.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Muvalaplin as an Inhibitor of Lipoprotein(a) Formation - 8 month(s) ago
This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in humans.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts - 8 month(s) ago
Nature Medicine – First-in-human results from five cohorts of healthy volunteers and individuals with hepatic steatosis show that RNA interference treatment targeting ANGPTL3 was well tolerated and…
Source: www.nature.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Local GP leaders across the south of England have told practices not to follow the NHS’s advice to prescribe the cholesterol lowering drug inclisiran because of concerns over funding and long term safety monitoring. The pushback comes amid a drive by NHS England, which published funding guidance in April 2023,1 and local integrated care boards (ICBs) to make the drug available in primary care to help tackle cardiovascular disease. The National Institute for Health and Care Excellence (NICE) approved inclisiran—made by Novartis and marketed as Leqvio—in 2021,23 hailing it as “a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.” Administered by injection, inclisiran uses RNA interference to boost the liver’s ability to remove low density lipoprotein cholesterol (LDL-C) from the blood. However, the BMA, the Royal College of General Practitioners,45 and experts writing in The BMJ 6 have raised concerns about inclisiran being ini
Source: www.bmj.comCategories: Cardiologists, Latest HeadlinesTweet
Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of #LLT https://t.co/awCDGLRa3W